NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17 ...

Humacyte, Inc. executives and board members failed to root out manufacturing compliance issues, delaying Food and Drug Administration permission to distribute its lab-grown blood vessel implant and ...

LOS ANGELES, Jan. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the ...

that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma ...

LOS ANGELES, Jan. 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Humacyte ...

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles ...

reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA ) for violations of the federal securities laws. Shareholders who bought the Company's ...